Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals
Cryoport Inc CYRX
$17.41
▲ +0.06%
(+$0.01)
Open
$17.36
Prev Close
$17.40
Day Range
$17.22 – $17.59
52W Range
$7.61 – $17.98
Market Cap
$881.80M
P/E (TTM)
11.22
Beta
1.91
EPS (TTM)
$-0.75
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-07-24 |
| Shares Out. | 50,400,000 |
| Website | cryoport.com/ ↗ |
| Phone | 19492321900 |
| Employees | 738 |
| Revenue | $49.0M |
| Gross Profit | $22.8M |
| Net Income | -$8.3M |
| Free Cash Flow | -$20.0M |
| Total Assets | $756.2M |
| Total Liabilities | $265.5M |
| Equity | $490.7M |
About Cryoport Inc
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Cryoport Inc is a publicly traded company under the ticker symbol CYRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)